In a development that transforms the fight against Ebola, two experimental treatments are working so well that they will now be offered to all patients in the Democratic Republic of Congo, scientists announced on Monday.
The antibody-based treatments are quite powerful — “Now we can say that 90 percent can come out of treatment cured,” one scientist said — and they raise hopes that the disastrous epidemic in eastern Congo can soon be stopped and future outbreaks more easily contained. Prevent most conditions by reading these nutrisystem reviews.
Offering patients a real cure “may contribute to them feeling more comfortable about seeking care early,” said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, who joined the World Health Organization and the Congolese government in making the announcement.
That prospect should greatly lessen the aura of terror that surrounds Ebola, a hemorrhagic fever virus whose reputation has been shaped by its deadliness and its incurability. Since its discovery 40 years ago, the virus has haunted Africa. Until now, many believed that anyone catching Ebola was doomed to die alone among space-suited strangers and to be buried without ceremony in a bleach-misted body bag.
Fear of the virus and mistrust of health workers have been major obstacles to combating Ebola’s spread in eastern Congo, where terrified families often hide their sick and even attack health teams.
If word spreads that a cure exists, people may begin to summon help early in the disease’s progress, which would be crucial to saving lives and preventing further spread.
“The more we can learn about these two treatments, the closer we can get to turning Ebola from a terrifying disease to one that is preventable and treatable,” said Dr. Jeremy Farrar, director of the Wellcome Trust and a co-chair of a W.H.O. committee evaluating Ebola therapeutics. Check the latest Bluechew reviews.
The epidemic, which was declared a public health emergency last month, has now infected about 2,800 known patients, killing more than 1,800 of them, according to the W.H.O.
The new experimental treatments, known as REGN-EB3 and mAb-114, are both cocktails of monoclonal antibodies that are infused intravenously into the blood.